Aims: Our purpose was to report the clinical and pathological findings from uveal melanoma patients with persistent exudative retinal detachment (RD) after Gamma Knife radiosurgery (GKR). Methods: A retrospective review was performed. Results: GKR was performed on 19 uveal melanoma patients from 2004 to 2006, and 5 of them developed persistent exudative RD. The mean initial largest basal tumor diameter in these 5 patients was 14.4 ± 1.9 mm, and the mean tumor height was 9.2 ± 1.0 mm. Marginal doses of 40–50 Gy radiation were administered. RD developed or had become aggravated an average of 3 (1–10) months after GKR. Two patients underwent enucleation, while the remaining 3 underwent tumor removal by endoresection with retinal reattachment surgery by vitrectomy and silicone oil tamponade. These procedures were undertaken an average of 6.3 (1.5–14) months after radiation and 3.3 (0.5–5) months after the onset or aggravation of RD. Histologically 4 tumors showed 50–100% necrosis without any mitotic activity. Thus local tumor control after GKR appeared sufficient regardless of RD. Conclusion: Aggravation or development of exudative RD after GKR does not necessarily entail treatment failure. Therefore, retinal reattachment surgery in persistent exudative RD may be an option to preserve the eye.

Keywords:
Gamma Knife radiosurgery, Uveal melanoma, Retinal detachment, Histopathology after radiation
1.
Char DH, Quivey JM, Castro JR, Kroll S, Phillips T: Helium ions versus iodine-125 brachytherapy in the management of uveal melanoma: a prospective, randomized, dynamically balanced trial. Ophthalmology 1993;100:1547–1554.
2.
Gragoudas ES, Marie Lane A: Uveal melanoma: proton beam irradiation. Ophthalmol Clin North Am 2005;18:111–118.
3.
Collaborative Ocular Melanoma Study (COMS) Group: The COMS randomized trial of Iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006;124:1684–1693.
4.
Marchini G, Gerosa M, Piovan E, Pasoli A, Babighian S, Rigotti M, Rossato M, Bonomi L: Gamma Knife stereotactic radiosurgery for uveal melanoma: clinical results after 2 years. Stereotact Funct Neurosurg 1996;66:208–213.
5.
Langmann G, Pendl G, Klaus-Müllner, Papaefthymiou G, Guss H: Gamma Knife radiosurgery for uveal melanomas: an 8-year experience. J Neurosurg 2000;93:184–188.
6.
Mueller AJ, Talies S, Schaller UC, Horstmann G, Wowra B, Kampik A: Stereotactic radiosurgery of large uveal melanomas with the gamma-knife. Ophthalmology 2000;107:1381–1388.
7.
Zehetmayer M, Kitz K, Menapace R, Ertl A, Heinzl H, Ruhswurm I, Georgopoulos M, Dieckmann K, Pötter R: Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. Radiother Oncol 2000;55:135–144.
8.
Simonova G, Novotny J Jr, Liscak R, Pilbauer J: Leksell gamma knife treatment of uveal melanoma. J Neurosurg 2002;97:635–639.
9.
Henderson MA, Shirazi H, Lo SS, Mendonca MS, Fakiris AJ, Witt TC, Worth RM, Timmerman RD: Stereotactic radiosurgery and fractionated stereotactic radiotherapy in the treatment of uveal melanoma. Technol Cancer Res Treat 2006;5:411–419.
10.
Wakisaka M, Mori H, Hongo N, Funakoshi T, Abe T, Mori T, Ishii Y, Yokoyama S: Correlation of pathological finding with dose distribution in a case of intraocular choroidal melanoma treated by stereotactic radiosurgery. Acta Oncol 2000;39:639–642.
11.
Damato B, Groenewald C, McGalliard J, Wong D: Endoresection of choroidal melanoma. Br J Ophthalmol 1998;82:213–218.
12.
Collaborative Ocular Melanoma Study Group: COMS Manual of Procedures. Accession No. PBS 179693. Springfield, National Technical Information Service, 1995.
13.
Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, Freire J: Plaque radiotherapy for large posterior uveal melanomas (≥8-mm thick) in 354 consecutive patients. Ophthalmology 2002;109:1838–1849.
14.
Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW: Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol 1999;117:170–177.
15.
Foss AJ, Whelehan I, Hungerford JL, Anderson DF, Errington RD, Kacperek A, Restori M, Konqerud J, Sheen M: Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol 1997;81:748–754.
16.
Puusaari I, Heikkonen J, Kivelä T: Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology 2004;111:1768–1777.
17.
Messmer E, Bornfeld N, Foerster M, Schilling H, Wessing A: Histopathologic findings in eyes treated with a ruthenium plaque for uveal melanoma. Graefe’s Arch Clin Exp Ophthalmol 1992;230:391–396.
18.
Saornil MA, Fisher MR, Campbell RJ, Robertson DM, Earle JD, Eagle RC Jr, Shields JA, Shields CL, Chandra SR, Albert DM: Histopathologic study of eyes after iodine I 125 episcleral plaque irradiation for uveal melanoma. Arch Ophthalmol 1997;115:1395–1400.
19.
Singh AD, Eagle RC Jr, Shields CL, Shields JA: Enucleation following transpupillary thermotherapy of choroidal melanoma: clinicopathologic correlations. Arch Ophthalmol 2003;121:397–400.
20.
Journée-de Korver JG, Oosterhuis JA, de Wolff-Rouendaal D, Kemme H: Histopathological findings in human choroidal melanomas after transpupillary thermotherapy. Br J Ophthalmol 1997;81:234–239.
21.
Diaz CE, Capone A Jr, Grossniklaus HE: Clinicopathologic findings in recurrent choroidal melanoma after transpupillary thermotherapy. Ophthalmology 1998;105:1419–1424.
22.
Harbour JW, Ahmad S, El-Bash M: Rate of resolution of exudative retinal detachment after plaque radiotherapy for uveal melanoma. Arch Ophthalmol 2002;120:1463–1469.
23.
Foster WJ, Harbour JW, Holekamp NM, Shah GK, Thomas MA: Pars plana vitrectomy in eyes containing a treated posterior uveal melanoma. Am J Ophthalmol 2003;136:471–476.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.